Cilag is a finished-dose manufacturer based in Switzerland. It holds 4 active US drug master files across a filed portfolio of 5 molecules. Its filings concentrate with ARCSA (EC), MINSA (CR) and INVIMA (CO). Its GMP standing is certified by ANVISA (Brazil), EMA and NAFDAC (NG). Its most recent recorded inspection, by US FDA, closed on 5 May 2023 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Schaffhausen, United Arab Emirates | Not on file |
| SCHAFFHAUSEN, Switzerland | Not on file |
| Switzerland, Switzerland | 3002806695 |
| schaffhausen, Nigeria | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Cladribine | SFDA (Saudi Arabia), US FDA | 2 |
| Alcaftadine | US FDA | 1 |
| Iron | US FDA | 1 |
| Iron Sucrose | SFDA (Saudi Arabia) | 1 |
| Remifentanil | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 16 | None |
| MINSA (CR) | 15 | None |
| INVIMA (CO) | 11 | None |
| NAFDAC (NG) | 3 | 2 |
| ANVISA (Brazil) | None | 5 |
| EMA | None | 4 |
Choose your molecules and target markets. Cilag comes back tiered against every other supplier able to file there.
Start for free